2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Angeles A. Secord, MD, discusses the individual therapeutic preferences and treatment considerations for patients with platinum-sensitive ovarian cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Angeles A. Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses the individual therapeutic preferences and treatment considerations for patients with platinum-sensitive ovarian cancer.
If a patient does not wish to undergo chemotherapy, it important to understand any specific concerns regarding toxicity, according to Secord. However, PARP inhibitors represent a feasible option for these patients Secord says. Trials such as the phase 3 GY004 trial (NCT02446600) and phase 3 SOLO-3 (NCT02282020) with olaparib (Lynparza), and the phase 3 ARIEL4 trial (NCT02855944) with rucaparib (Rubraca), have demonstrated that patients with BRCA1/2 mutations can achieve robust responses and disease control on these drugs, Secord explains.
Another consideration is the goal of therapy, in terms of avoiding toxicity and maximizing quality-of-life, Secord notes. Often, these goals are not the same for all patients, Secord continues. For example, although some patients may prefer oral therapy with a pill, others may prefer IV therapy. As such, these conversations with patients are crucial, Secord concludes.
Related Content: